XML 15 R6.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash flows used in operating activities:    
Net loss $ (12,978) $ (13,316)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 723 628
Amortization of deferred financing costs and debt discount 20 190
Common stock issued for research and development   75
Accretion of discount on short-term investments (111)  
Non-cash financing expenses 3,545  
Change in fair value of warrants (5,654)  
Loss on disposal of property and equipment   2
Share-based compensation expense 550 569
Reduction in the carrying amount of operating lease right-of-use assets 129 117
Increases (decreases) in cash caused by changes in operating assets and liabilities:    
Grant receivable (571)  
Other assets 218 2,397
Accounts payable and accrued expenses 4,702 (3,677)
Change in operating lease liabilities (130) (117)
Deferred grant liability (997) 281
Net cash used in operating activities (10,554) (12,851)
Cash flows used in investing activities:    
Purchases of property and equipment (146) (160)
Purchases of intangible assets (545)  
Purchases of short-term investments (15,590)  
Redemption of short-term investments 12,170  
Net cash used in investing activities (4,111) (160)
Cash flows from financing activities:    
Principal payments of long-term obligations (3,996) (1,608)
Proceeds from credit facility 3,292  
Proceeds from sale of common stock warrants and pre-funded warrants, net 7,265  
Proceeds from sale of common stock, net of offering costs of $0.2 million   5,527
Payment of offering costs related to sale of common stock   (348)
Purchase of treasury stock (374) (126)
Net cash provided by financing activities 6,187 3,445
Net decrease in cash and cash equivalents (8,478) (9,566)
Cash and cash equivalents at beginning of period 8,554 18,120
Cash and cash equivalents at end of period 76 8,554
Cash paid during period for:    
Interest $ 32 222
Supplemental schedule of non-cash investing and financing activities:    
Unpaid offering cost   174
Common stock issued in payment for in process research and development   75
Right-of-use assets acquired by assuming operating lease liabilities   $ 71